Patents Assigned to Genzyme Corporation
  • Patent number: 11957765
    Abstract: The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: April 16, 2024
    Assignee: Genzyme Corporation
    Inventors: Marco A. Passini, James Dodge
  • Publication number: 20240117028
    Abstract: A modified IgG antibody binds and neutralizes TGF?l selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 11, 2024
    Applicant: Genzyme Corporation
    Inventors: Huawei QIU, Julie BIRD
  • Publication number: 20240110168
    Abstract: The present invention relates to a method of producing a polypeptide having ?-hexosaminidase activity, comprising the steps of a) providing a yeast cell comprising a polynucleotide encoding a polypeptide having ?-hexosaminidase activity and having an amino acid sequence being at least 95% identical to the amino acid sequence shown in SEQ ID NO: 1, b) cultivating said yeast cell under conditions which allow for the production of the polypeptide, and c) obtaining the polypeptide produced in step b). The present invention further concerns a polynucleotide encoding a polypeptide having ?-hexosaminidase activity and having an amino acid sequence being at least 95% identical to the amino acid sequence shown in SEQ ID NO: 1, as well as polypeptide encoded by said polynucleotide. Moreover, the present invention concerns a yeast cell comprising the polynucleotide of the present invention.
    Type: Application
    Filed: December 2, 2021
    Publication date: April 4, 2024
    Applicant: Genzyme Corporation
    Inventors: Sebastian RISSOM, Ava CHATTOPADHYAY, Werner DITTRICH, Thomas Martin WENDRICH
  • Patent number: 11945874
    Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: April 2, 2024
    Assignee: Genzyme Corporation
    Inventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
  • Publication number: 20240100065
    Abstract: This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors, to treat a receptor-interacting protein kinase 1-mediated disease or disorder.
    Type: Application
    Filed: August 22, 2023
    Publication date: March 28, 2024
    Applicant: Genzyme Corporation
    Inventors: Nazem Atassi, Catherine Cantalloube, Agn├Ęs Hincelin-Mery, Donato Teutonico
  • Patent number: 11927596
    Abstract: Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: March 12, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Ryan Grabert, Susan Richards, Valerie Theobald, Yuanxin Xu, Jad Zoghbi
  • Patent number: 11920120
    Abstract: Provided herein are isolation processes and the associated hardware to allow fluid streams to be isolated from a sterilized system (e.g., a sterile process vessel) that contains a sterile process. The isolation processes described herein allow for continuous removal of fluid streams (e.g., waste streams, liquid containing recombinant therapeutic proteins) from a sterilized system (e.g., a biological manufacturing system), which provides for less manual manipulation of the sterilized system and a decreased risk of contaminating the sterilized system.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: March 5, 2024
    Assignee: Genzyme Corporation
    Inventor: Robert Snow
  • Patent number: 11912741
    Abstract: The present disclosure relates to methods and systems for the continuous production of recombinant proteins. In particular embodiments, the disclosure relates to methods and systems using capture chromatography, post-capture chromatography, virus filtration, and ultrafiltration/diafiltration for the continuous production of recombinant proteins.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: February 27, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Michael Coolbaugh, Tarl Vetter, Chad Varner, Kevin Brower
  • Patent number: 11912739
    Abstract: Provided herein are methods of performing chromatography with gamma-irradiated chromatography resin that include providing a chromatography column including a gamma-irradiated chromatography resin; performing a first cycle of chromatography through the column, where the cycle includes exposing the chromatography resin to a denaturing buffer; and performing at least one additional cycle of chromatography through the column. Also provided are integrated, closed or substantially closed, and continuous processes for manufacturing of a recombinant protein that include the use of at least one chromatography column including gamma-irradiated chromatography resin, where the gamma-irradiated chromatography resin is exposed to denaturing buffer during each cycle in the process, and reduced bioburden buffer is used in the process.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: February 27, 2024
    Assignee: Genzyme Corporation
    Inventors: Rahul Godawat, Veena Warikoo, Rohan Patil, Konstantin Konstantinov, Venkat Kishore Ryakala, Mahsa Rohani
  • Patent number: 11911440
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: February 27, 2024
    Assignee: Genzyme Corporation
    Inventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
  • Patent number: 11905531
    Abstract: The present disclosure relates to recombinant viral vectors, to pharmaceutical compositions comprising such recombinant vectors, and to methods for prevention and treatment of osteoarthritis in mammals. In particular, this disclosure provides adeno-associated virus (AAV) vectors capable of expressing, in a host, osteoprotective/chondroprotective bioactive proteins, including hyaluronan synthase 2 (HAS2) and lubricin (PRG4). Methods of production of these AAV are provided, as are methods of treatment of osteoarthritis in mammalian joints, by the long-term gene expression of osteoprotective/chondroprotective proteins, including HAS2 and PRG4, in both synovial and chondrocyte cells.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: February 20, 2024
    Assignees: GENZYME CORPORATION, BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Monica Dias Figueiredo, Sirkka R M Kyostio-Moore, Patricia Berthelette
  • Publication number: 20240051955
    Abstract: The present disclosure relates to 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one variants or derivatives, and salts thereof, for use as agonists and antagonists. The disclosure further relates to compositions, methods of preparing, and methods of treatment.
    Type: Application
    Filed: December 22, 2021
    Publication date: February 15, 2024
    Applicant: Genzyme Corporation
    Inventors: Catherine Arabeyre, Patricia Moliner, Sabine Boisnard, Damien Sallaberry, Serge Perard, Sebastien Roy
  • Patent number: 11897876
    Abstract: The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: February 13, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Elisabeth Defossa, Uwe Heinelt, Hans Matter, Maria Mendez-Perez, Nils Rackelmann, Kurt Ritter, Hauke Szillat, Gernot Zech
  • Patent number: 11896651
    Abstract: Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system. In some aspects, provided herein is a self-limiting CRISPER-Cas system.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 13, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Guoxiang Ruan, Abraham Scaria
  • Patent number: 11898175
    Abstract: The invention provides methods of using a human acid sphingomyelinase (e.g., olipudase alfa) in treating an abnormal bone condition in acid sphingomyelinase deficiency patients such as low bone density, high bone marrow burden, and other skeletal abnormalities presented in acid sphingomyelinase deficiency patients.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: February 13, 2024
    Assignee: Genzyme Corporation
    Inventor: Ana Cristina Scheidt-Puga
  • Publication number: 20240033323
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Application
    Filed: October 17, 2023
    Publication date: February 1, 2024
    Applicant: Genzyme Corporation
    Inventors: Marco A. PASSINI, Lamya Shihabuddin, Seng H. Cheng
  • Patent number: 11884703
    Abstract: Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit. Also provided are integrated and continuous processes for manufacturing a therapeutic protein drug substance that include a step of processing a fluid including the recombinant therapeutic protein using any of the methods provided herein.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: January 30, 2024
    Assignee: Genzyme Corporation
    Inventors: Tarl Vetter, Michael Coolbaugh, Veena Warikoo, Konstantin Konstantinov
  • Publication number: 20240027478
    Abstract: The present disclosure provides a method that aims to maintain a favorable benefit-risk balance for patients with hemophilia A or B with or without inhibitors treated with fitusiran.
    Type: Application
    Filed: December 6, 2021
    Publication date: January 25, 2024
    Applicant: Genzyme Corporation
    Inventors: Stacey Poloskey, Shauna Andersson, Pratik R. Bhagunde, Yue Cui, Sajida Iqbal, Baisong Mei
  • Patent number: 11878024
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: January 23, 2024
    Assignee: GENZYME CORPORATION
    Inventors: John L. Kane, Jr., Gloria Matthews, Markus Metz, Michael Kothe, Jinyu Liu, Andrew Scholte
  • Patent number: 11879004
    Abstract: Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 23, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Qun Zhou, Sunghae Park, Huawei Qiu, Marie-Priscille Brun, Francis Duffieux